Sesha Neervannan, PhD

Chief Operating Officer, Tarsus Pharmaceuticals Inc.

Sesha is currently the Chief Operating Officer at Tarsus Pharmaceuticals Inc responsible for Operations and R&D, where he helped develop and gain approval for XDEMVY®, the only FDA approved treatment for Demodex Blepharitis. Sesha has over 25 years of experience with the global drug development of novel therapeutics including eyecare. Prior to joining Tarsus, he was a Senior Vice President of Global Pharmaceutical Development at Allergan, where he led a strong drug development organization for product approval and commercialization of small molecules and biologics. He established an industry-leading expertise in ocular drug delivery technologies and helped develop several novel intraocular, sustained-release injectables for both anterior and posterior segments as well as several Rx and OTC topical ophthalmic products for glaucoma and ocular surface diseases. Prior to Allergan, Sesha led product development at Amgen and Bristol-Myers Squibb. Sesha has a Ph.D. in pharmaceutical chemistry, with honors, from the University of Kansas.